Showing results (361-370 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|February 5, 2021
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trialFabio Gomes, Corinne Faivre-Finn, Hitesh Mistry, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statementNeal Navani, Rachel Butler, Salma Ibrahimo, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2022
Organoids in lung cancer: A teenager with infinite growth potentialYiming Xu, Wanghao Xin, Chao Yan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|October 25, 2022
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohortLukas Bubendorf, Martin Zoche, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2015
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2015
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancerAkihiro Nishiyama, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2015
Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinomaKyuichi Kadota, Daniel Buitrago, Ming-Ching Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2015
Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2Luciene Schluckebier, Osvaldo U Garay, Mauro Zukin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2015
Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in non-small cell lung cancer that drives the EMT phenotypeLiyi Zhang, Jianzhi Zhang, Yuanyuan Ma, et al.
Pageof 701